Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

Drug development in hematology-oncology can sometimes happen at such a fast, paradigm-busting pace that the selection of treatments even 20 years ago can look like prehistory compared to what is available now. Few indications exemplify such rapid change more than multiple myeloma – where small molecule drugs that have long served as backbone treatments are going generic, new biologics with novel targets have rapidly become backbone treatments themselves, and other drugs with new mechanisms have struggled to gain widespread acceptance.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

07 Jan 2025

• By Alaric DeArment

IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.

Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow

11 Dec 2024

• By Jessica Merrill

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

29 Jul 2023

• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.